• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Economy The least thing politicians can do when China attacks our medicine supply
Economy

The least thing politicians can do when China attacks our medicine supply

by October 5, 2023
by October 5, 2023 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

COVID exposed the danger of being heavily reliant on a foreign country for medications and medical supplies when China and other countries put a halt on PPE and other exports. As a result of inaction, we are seeing headlines announcing medication shortages of life-saving drugs, like chemotherapeutics, and generics like amoxicillin are higher than ever.

All Americans, not only those in medical professions, should share the same grave concerns expressed by former U.N. Ambassador Nikki Haley at the recent presidential primary debate. For decades, administrations from both political parties have sat idly by while America’s pharmaceutical manufacturing moved overseas, primarily to China and India. 

Haley is right when she said, ‘We need to be focusing on companies that produce in America and supporting those companies that produce in America; not companies that are helping China.’

It is a national security and public health crisis that nearly 90% of the chemical ingredients needed to make antibiotics and other medications are sourced from China. And it’s not just the ingredients. Our government is purchasing final products from China too. 

Our troops and our entire population are at risk when an adversary has the ability to provide tainted or ineffective products, if they provide them at all. Until we control our medication supply chain, we are at risk.

In 2015, China’s government released a 10-year plan to dominate 10 high-tech industries, especially geopolitically important sectors like bio-medicine. They directed enormous subsidies into these industries and implemented policies that favored their domestic companies while punishing any foreign competition. Since 2016, U.S. pharmaceutical imports from China have climbed 655%. This reliance is worst when it comes to antibiotics.

A pharmaceutical plant in Bristol, Tennessee, USAntibiotics, is the only remaining American manufacturer of amoxicillin finished doses. At its peak, the plant employed more than 500 American workers and manufactured ‘billions of pills,’ but as is the case of many American pharmaceutical manufacturing plants, has faced challenges in its over 30-year history.

The federal government is supporting Chinese manufacturers while plants like the one in Tennessee, are overlooked. Opportunities to strengthen our domestic supply chain are missed. This is in stark contrast to governments around the world, including Austria and France who have committed $53 million and $168 million to support their domestic antibiotics operations. 

If our federal government would redirect these contracts to domestic companies, then they would be able to expand operations, create stable jobs and improve national security.

As China aims to achieve dominance in these industries by 2049 – the hundredth anniversary of the People’s Republic of China – our vulnerability is only likely to get worse. With our health industrial base on life support, we are already facing shortages of key drugs and costly disruptions that inevitably occur when you are relying on a supplier like China.

As China continues to attack one of our most vital industries, federal leaders have a choice to make. Purchasing from American manufacturers should be the easy part of this challenge. Politicians love to talk buy American on the campaign trail because voters overwhelmingly recognize why it’s important. 

We must put those campaign promises into action. When the stakes are this high, the least the federal government can do is the bare minimum.

President Biden didn’t create this problem, but he has the opportunity to do something about it. All Americans benefit when critical medications and their ingredients are manufactured in America. This bipartisan issue deserves action now before we have another crisis and the most vulnerable Americans suffer due to a lack of this life-saving medication. 

It’s time to prioritize domestic pharmaceutical manufacturing to enhance our national and public health security.

Marion Mass, M.D., is the co-founder of Practicing Physicians of America and helps lead the nonprofit Free2Care Coalition.

This post appeared first on FOX NEWS
You Might Also Like
  • Five areas could tell us a lot about the GOP on Super Tuesday
  • GOP blasts Dems’ ‘out-of-touch’ warning of no more White House Correspondents’ Dinners if Trump wins election
  • Sen Cruz leads push to reintroduce ‘Kate’s Law’ to jail repeat illegal immigrants
  • Vivek Ramaswamy on 9/11: ‘I don’t believe the government has told us the truth’
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Vivek Ramaswamy says ‘no better plan’ than McCarthy removal, lawmakers should ‘own it’
next post
McConnell praises ousted Speaker McCarthy for ‘thankless role’ in House

You may also like

Where Do The Savings Go?

December 28, 2022

New Jersey passes campaign finance overhaul into law

March 31, 2023

Former Nancy Mace staffers working with ex-chief of staff to...

January 20, 2024

When Federal Interest Payments Come to Exceed the Military Budget:...

January 5, 2023

Biden admin continues push for two-state solution as critics warn:...

January 12, 2024

Netanyahu reportedly upset with Harris over VP’s Israel remarks as...

July 26, 2024

530K Alabama children eligible for summer food benefits

March 15, 2023

Can Joe Biden be replaced as the sitting president?

June 29, 2024

Ripple and Tron: Ripple faces new resistance on Thursday

September 13, 2024

Ohio Republicans look to place restrictions on future ballot initiatives,...

May 15, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Week Ahead: NIFTY Stays In A Defined Range; Moving Past This Level Crucial For Resumption Of Upmove

      May 31, 2025
    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025
    • Run Your Stock Portfolio Like a Pro Sports Team

      May 30, 2025
    • U.S. foreign tax bill sends jitters across Wall Street

      May 30, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,765 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,472 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,451 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,432 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,308 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,582)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Week Ahead: NIFTY Stays In A Defined Range; Moving Past...

      May 31, 2025
    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right...

      May 31, 2025
    • Leadership Rotation Could Confirm Corrective Phase

      May 30, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,106)
    • Investing (538)
    • Stock (2,582)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Walz’s honeymoon with China gets fresh...

    August 9, 2024

    IG report finds Pentagon failed to...

    January 12, 2024

    Minnesota Rep. Angie Craig credits morning...

    February 11, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here